Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q34060237

about

Trial Watch Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation Expanding role of lenalidomide in hematologic malignancies Rational Combinations of Targeted Agents in AML International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.Lenalidomide as a novel treatment of acute myeloid leukemia.The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Novel therapies for children with acute myeloid leukaemia.Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.The changing landscape of phase I trials in oncology.Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.DNA methyltransferase inhibitors: an updated patent review (2012-2015).Hypomethylating Agents as a Therapy for AML.Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.Retinoid differentiation therapy for common types of acute myeloid leukemia.Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.Trial Watch: Lenalidomide-based immunochemotherapy.CNS Involvement in AML Patient Treated with 5-Azacytidine Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.Cancer epigenetics: new therapies and new challenges.Expert insights into the contemporary management of older adults with acute myeloid leukemia.

P2860

Q24618653-8D134097-BC22-465E-AF78-EEC6426585F8 Q24632949-B58DABE9-E5C7-46AD-A609-B8718B903B71 Q26827079-65EAA15A-E46C-4076-BAD8-9FEF232ACCAC Q33406770-A74BC05F-572F-4934-BCD2-0F654C9AEB1C Q33434768-96D3AF82-AC0A-46CE-85FE-13FBC9470285 Q34342944-0FF14744-A2C7-48EB-8160-85880D2B28D5 Q34861985-B5E90D38-A1D1-4AC1-9DB5-EA351F2E8F8D Q35592305-7ED80320-5FE4-4A6D-A4E4-69B07FDFC6EF Q35750491-8F9D41FE-83E5-486E-9A2E-D72CFDD56F32 Q35859212-E6EC6160-6D96-4647-B870-DC6CC11FD8A7 Q36474572-22E1E68D-A83B-4BCD-9A95-7FCFE0D899FC Q36862505-25DA7747-369A-41E9-897E-0652417C160C Q36944013-C5461789-CD30-4D80-94A1-7933BAF3D241 Q37216367-B9E46FD3-1AB7-4387-B2EC-E838CB8718F4 Q37299309-F5A1BE70-73D9-4076-BB20-5FC5594ED37C Q37635209-CFD45A8B-FE90-47C7-B7FF-F52177F5EF1A Q37702336-2BDE84C5-8E76-42B0-98B4-12AE86B7E154 Q38073811-E72B6D80-A421-4A87-B056-A88CC995F5F6 Q38083604-FC37C50E-B66F-4216-8EC7-745D6508A0C0 Q38091393-B246EFAA-1E39-45E8-A7EF-34EF4243262C Q38096798-5AA2D9D7-319A-45BF-9CF3-A26E0AD4E4D4 Q38115584-56A8D6AE-074C-45D8-8E7F-0CBDFA43A9C3 Q38250205-34C6EBCD-0BB3-40C8-89BA-58FF0B363821 Q38629203-A52E8566-7E16-4A52-B26E-44CB07F7481E Q38730411-E13BFAFC-D1DF-4BC4-896C-5A57CA890AE4 Q38810393-3E8DAC26-8C8F-4B2B-BD84-56146422CEBA Q38885370-F89D9240-E92A-4865-8F74-396525AF0694 Q38911864-76FEAA72-8737-4818-8FF1-6938842F5252 Q39205106-D83B8149-DF93-4722-A380-AC4568B6CC96 Q39527812-C589FCD2-0CE2-4703-83A1-655FE97DE298 Q40139200-4A98D8A2-AA53-420C-A87F-08694E453CC3 Q41080080-67634922-33D9-4FA9-AFD4-03BF48E6D897 Q41509184-FE3F24F1-C52B-4DE1-A89F-8009C260EEFC Q41723841-8B69976B-EA80-4E04-90EB-13EDCD6D0E62 Q41939573-61B51915-3B2F-4DAE-9B7A-CBBFFE357F81 Q42737828-9CD97487-4D50-4E10-84C9-369F39635548 Q42853619-75ED82D1-A611-464A-947D-86CDAE269712 Q43134067-02689B52-A1D4-4943-BA7C-362C2AE13C1C Q43226742-AA35F3D4-DE0C-42CD-BBE6-ECDD370E4241 Q44898238-F3D87A14-2863-417B-BC7A-46BE516647D3

P2860

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q34060237

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@ast

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@en

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@nl

type

label

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@ast

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@en

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@nl

prefLabel

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@ast

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@en

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@nl

P1433

Q34060237-BDD62535-6224-4156-9129-AB0A0B6EC2ED

P1476

Q34060237-15AE0677-DDB8-4F8D-B927-AFEA93823664

P2093

Q34060237-085D7D26-DC27-4E02-8146-9C427AFB2BE9

Q34060237-1D53A6D4-7F09-483E-9034-B818A51289B7

Q34060237-41CE650B-4773-46B6-BFE7-579BD4D88B22

Q34060237-4668973A-C7E8-4221-99CA-A3E67BBACCE0

Q34060237-55FBCA0A-7C06-4D7B-B54A-B4471F95C3E4

Q34060237-58B20811-D96A-4576-A0F2-770961D3A04A

Q34060237-5A4848EE-9EB0-4B8D-B941-3379C9D9D9F9

Q34060237-69C4AE41-C2F1-4123-9073-631496D60905

Q34060237-75850A8E-7ACE-4456-9448-6E6D392F6DE6

Q34060237-8311761E-CDF3-4ECC-B257-7FABBAA9AC35

P2860

Q34060237-11C09BD8-A534-4A66-8F45-C96CF1B214C8

Q34060237-126631B8-004E-4417-881A-3199DDA70414

Q34060237-1A7AFBE7-57AA-4646-BB78-F40887579C79

Q34060237-1F5B3FF1-523B-4C0C-BC88-2568210517F1

Q34060237-2180789C-6294-4BD2-A29E-56D91A5EAD28

Q34060237-23E3A8AA-2C72-45F4-963A-8F6C199EB996

Q34060237-25948870-53E8-41F7-9C4D-B049794B43DE

Q34060237-25C42C39-F5D9-44F6-BBEE-A63473C5FAA2

Q34060237-2D1691E1-E245-4171-8CE4-4C5012A4E181

Q34060237-3FD51CD6-EDF0-4E83-B9CD-6F6627F5CDAD

P2888

Q34060237-250E88F5-85E3-47EF-9518-3E363B1CD44F

P304

Q34060237-135DF8BA-72A1-4D10-875A-53FE801ECC05

P31

Q34060237-9C638462-D5F4-436E-9E58-CCEA23F7EE92

P356

Q34060237-7319691C-3D9A-42F2-94EB-9E5C39ECB55A

P433

Q34060237-5C327EBF-5740-4FB3-B954-86F31D79F46A

P478

Q34060237-85890094-BD59-4500-B3FB-F9BEF0F2234E

P577

Q34060237-D9B5994E-5BF9-4D7A-9DD7-F76652DFDBBF

P6179

Q34060237-5F811F2C-6819-492B-8880-57EB1713BA3D

P698

Q34060237-66788F5F-EB83-4ED3-B6FC-A6DE75CEDB1A

P921

Q34060237-03D99E54-FAE3-42A2-A5B4-8252AB0F9C3A

Q34060237-71DA770C-05A8-400F-B4E9-3E617148F5B8

P356

P1433

P1476

Safety, efficacy and biologica ...... s with acute myeloid leukemia.

@en

P2093

A Melnick

http://www.w3.org/2001/XMLSchema#string

B C Medeiros

http://www.w3.org/2001/XMLSchema#string

B S Mitchell

http://www.w3.org/2001/XMLSchema#string

B Zhang

http://www.w3.org/2001/XMLSchema#string

C Berube

http://www.w3.org/2001/XMLSchema#string

D A Pollyea

http://www.w3.org/2001/XMLSchema#string

H E Kohrt

http://www.w3.org/2001/XMLSchema#string

J R Gotlib

http://www.w3.org/2001/XMLSchema#string

J Zehnder

http://www.w3.org/2001/XMLSchema#string

L Gallegos

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Comparative isoschizomer profiling of cytosine methylation: the HELP assay

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Aging, DNA methylation and cancer.

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

P2888

P304

893-901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2011.294

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003412769

http://www.w3.org/2001/XMLSchema#string

P698

22033493

http://www.w3.org/2001/XMLSchema#string

P921